This Article Full Text Full Text (PDF) All Versions of this Article: 46/4/637    most recent 01.HYP.0000184541.24700.c7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nathan, S. Articles by Bakris, G. L. Search for Related Content PubMed PubMed Citation Articles by Nathan, S. Articles by Bakris, G. L. Pubmed/NCBI databases Medline Plus Health Information Heart Diseases High Blood Pressure Kidney Diseases Related Collections Other Stroke Treatment - Medical Clinical Studies Other diabetes Other Treatment

(Hypertension. 2005;46:637.)
© 2005 American Heart Association, Inc.

Hypertension Grand Rounds

Calcium Antagonists

Effects on Cardio-Renal Risk in Hypertensive Patients

From the Department of Preventive Medicine (S.N., G.L.B.), Hypertension/Clinical Research Center, Rush University Medical Center and Department of Medicine (C.J.P.), Division of Cardiovascular Medicine, University of Florida, College of Medicine, Gainsville, Fla.

Correspondence to George Bakris, MD, Rush University Medical Center, 1700 W Van Buren St, Ste 470, Chicago, IL 60612. E-mail gbakris{at}earthlink.net

Calcium antagonists comprise 2 main subclasses, dihydropyridines and nondihydropyridines, and have been studied extensively in hypertensive patients. Early meta-analyses suggested that short-acting calcium antagonists were associated with higher mortality rates resulting from cardiovascular events and other etiologies. Recent meta-analyses failed to show any substantive difference between long acting calcium antagonists and other antihypertensive drug classes with regard to cardiovascular outcomes in those with low to moderate cardiovascular risk or kidney disease progression among those with stage 2 or 3 nonproteinuric kidney diseases. The data from calcium antagonist trials are consistent in that they decrease stroke incidence but fail to protect against new-onset heart failure. In people with proteinuric kidney disease, that is >300 mg protein/gram creatinine, use of dihydropyridine calcium antagonists to lower blood pressure without the use of agents that block the renin angiotensin aldosterone system does not provide optimal slowing of nephropathy progression. This relates directly to lack of antiproteinuric effects with this subclass and not seen with nondihydropyridine agents that reduce proteinuria to a greater degree than dihydropyridines. Thus, calcium antagonists are safe and as efficacious as other antihypertensive agents to reduce cardiovascular risk. They should be avoided in people with systolic dysfunction but may be used for blood pressure lowering in people with preserved systolic function. Dihydropyridine calcium antagonists should only be used in conjunction with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in proteinuric kidney disease because they will not optimally slow kidney function loss in their absence.

Key Words: calcium antagonists • cardiovascular risk • hypertension • renal disease

This article has been cited by other articles:

				H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]

				B. Stults and R. E. Jones Management of Hypertension in Diabetes Diabetes Spectr, January 1, 2006; 19(1): 25 - 31. [Abstract] [Full Text] [PDF]